Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
yescarta | Biologic Licensing Application | 2023-12-26 |
Expiration | Code | ||
---|---|---|---|
axicabtagene ciloleucel, Yescarta, Kite Pharma Inc. | |||
2029-04-01 | Orphan excl. |
Code | Description |
---|---|
Q2041 | Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell lymphoma | D016393 | — | — | 2 | 8 | — | — | 1 | 10 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 4 | 5 | — | — | 1 | 8 |
Follicular lymphoma | D008224 | — | C82 | 2 | 4 | — | — | 1 | 6 |
Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | 1 | 4 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 2 | — | — | — | 4 |
Cytokine release syndrome | D000080424 | — | D89.83 | — | 2 | — | — | — | 2 |
Neurotoxicity syndromes | D020258 | — | G92 | — | 2 | — | — | — | 2 |
Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | — | — | — | 2 | 2 |
Drug common name | Axicabtagene ciloleucel |
INN | axicabtagene ciloleucel |
Description | Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow. Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities.
|
Classification | Gene |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | 1987398 |
ChEMBL ID | CHEMBL3989989 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB13915 |
UNII ID | U2I8T43Y7R (ChemIDplus, GSRS) |